001     140488
005     20240722132448.0
024 7 _ |a 10.1007/s00115-018-0601-6
|2 doi
024 7 _ |a pmid:30171304
|2 pmid
024 7 _ |a 0028-2804
|2 ISSN
024 7 _ |a 1433-0407
|2 ISSN
024 7 _ |a altmetric:47560826
|2 altmetric
037 _ _ |a DZNE-2020-06810
041 _ _ |a ger
082 _ _ |a 610
100 1 _ |a Bedarf, Janis
|0 P:(DE-2719)2811747
|b 0
|e First author
|u dzne
245 _ _ |a The gut microbiome in Parkinson's disease | Das Darmmikrobiom bei der Parkinson-Krankheit
260 _ _ |a Heidelberg
|c 2019
|b Springer
264 _ 1 |3 online
|2 Crossref
|b Springer Science and Business Media LLC
|c 2018-08-31
264 _ 1 |3 print
|2 Crossref
|b Springer Science and Business Media LLC
|c 2019-02-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1721647432_12030
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The vast majority of Parkinson's disease (PD) cases are of sporadic origin and despite extensive research in recent years, the etiology still remains unclear. Several current case control studies are aiming to characterize a putative PD-specific composition of the gut microbiome, reflecting the potential relevance of microbiota in the pathogenesis of PD. Although methodologies and cohort sizes differed, the currently available studies showed reproducible or consistent results in terms of PD-specific alterations to the intestinal bacteria. By applying metagenomic sequencing procedures, it is even possible to distinguish PD cases from healthy individuals at a very early disease stage by means of individually modified microbiota. Among others, microbiota that are associated with an altered intestinal barrier or immune function, such as Akkermansia, Lactobacillus, Faecalibacterium and Prevotella were significantly over-represented or under-represented. There may even be a prodromal microbiome, as a comparable microbial shift is also found in patients with rapid eye movement (REM) sleep behavior disorder (RBD), a risk factor for the later development of synucleinopathies, such as PD.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 1
542 _ _ |i 2018-08-31
|2 Crossref
|u http://www.springer.com/tdm
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 2 |a Case-Control Studies
|2 MeSH
650 _ 2 |a Gastrointestinal Microbiome
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Metagenome
|2 MeSH
650 _ 2 |a Parkinson Disease: diagnosis
|2 MeSH
650 _ 2 |a Parkinson Disease: microbiology
|2 MeSH
650 _ 2 |a REM Sleep Behavior Disorder: microbiology
|2 MeSH
700 1 _ |a Hildebrand, F.
|b 1
700 1 _ |a Goeser, F.
|b 2
700 1 _ |a Bork, P.
|b 3
700 1 _ |a Wüllner, U.
|0 P:(DE-2719)2000056
|b 4
|e Last author
|u dzne
773 1 8 |a 10.1007/s00115-018-0601-6
|b : Springer Science and Business Media LLC, 2018-08-31
|n 2
|p 160-166
|3 journal-article
|2 Crossref
|t Der Nervenarzt
|v 90
|y 2018
|x 0028-2804
773 _ _ |a 10.1007/s00115-018-0601-6
|g Vol. 90, no. 2, p. 160 - 166
|0 PERI:(DE-600)1462945-8
|n 2
|q 90:2<160 - 166
|p 160-166
|t Der Nervenarzt
|v 90
|y 2019
|x 0028-2804
856 4 _ |u https://pub.dzne.de/record/140488/files/DZNE-2020-06810.pdf
856 4 _ |u https://pub.dzne.de/record/140488/files/DZNE-2020-06810.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:140488
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2811747
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2000056
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NERVENARZT : 2021
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-12
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-12
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-12
920 1 _ |0 I:(DE-2719)1013022
|k AG Tamgüney 2
|l Prion and prion-like diseases
|x 0
920 1 _ |0 I:(DE-2719)1011302
|k AG Wüllner
|l Biomarker Parkinson's Disease
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1013022
980 _ _ |a I:(DE-2719)1011302
980 _ _ |a UNRESTRICTED
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.26702
|2 Crossref
|o 10.1002/mds.26702
999 C 5 |9 -- missing cx lookup --
|a 10.1186/s13073-017-0428-y
|2 Crossref
|o 10.1186/s13073-017-0428-y
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.molmed.2014.05.002
|2 Crossref
|o 10.1016/j.molmed.2014.05.002
999 C 5 |9 -- missing cx lookup --
|a 10.1101/cshperspect.a023630
|2 Crossref
|o 10.1101/cshperspect.a023630
999 C 5 |9 -- missing cx lookup --
|a 10.1038/nrmicro2876
|2 Crossref
|o 10.1038/nrmicro2876
999 C 5 |9 -- missing cx lookup --
|a 10.1038/s41564-017-0072-8
|2 Crossref
|o 10.1038/s41564-017-0072-8
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.nbd.2012.09.007
|2 Crossref
|o 10.1016/j.nbd.2012.09.007
999 C 5 |9 -- missing cx lookup --
|a 10.1111/2049-632X.12170
|2 Crossref
|o 10.1111/2049-632X.12170
999 C 5 |9 -- missing cx lookup --
|a 10.3389/fmicb.2016.00713
|2 Crossref
|o 10.3389/fmicb.2016.00713
999 C 5 |9 -- missing cx lookup --
|a 10.1038/nn.4030
|2 Crossref
|o 10.1038/nn.4030
999 C 5 |9 -- missing cx lookup --
|a 10.1073/pnas.1219451110
|2 Crossref
|o 10.1073/pnas.1219451110
999 C 5 |9 -- missing cx lookup --
|a 10.1371/journal.pone.0028032
|2 Crossref
|o 10.1371/journal.pone.0028032
999 C 5 |9 -- missing cx lookup --
|a 10.1371/journal.pone.0074963
|2 Crossref
|o 10.1371/journal.pone.0074963
999 C 5 |9 -- missing cx lookup --
|a 10.1371/journal.pone.0142164
|2 Crossref
|o 10.1371/journal.pone.0142164
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.27105
|2 Crossref
|o 10.1002/mds.27105
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.tim.2017.11.002
|2 Crossref
|o 10.1016/j.tim.2017.11.002
999 C 5 |9 -- missing cx lookup --
|a 10.1111/jnc.13593
|2 Crossref
|o 10.1111/jnc.13593
999 C 5 |9 -- missing cx lookup --
|a 10.1186/2049-2618-2-30
|2 Crossref
|o 10.1186/2049-2618-2-30
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.26942
|2 Crossref
|o 10.1002/mds.26942
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.brainres.2017.04.019
|2 Crossref
|o 10.1016/j.brainres.2017.04.019
999 C 5 |9 -- missing cx lookup --
|a 10.1371/journal.pone.0076520
|2 Crossref
|o 10.1371/journal.pone.0076520
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.chom.2015.03.005
|2 Crossref
|o 10.1016/j.chom.2015.03.005
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.26307
|2 Crossref
|o 10.1002/mds.26307
999 C 5 |9 -- missing cx lookup --
|a 10.1038/nrneurol.2015.197
|2 Crossref
|o 10.1038/nrneurol.2015.197
999 C 5 |9 -- missing cx lookup --
|a 10.1038/nm.4102
|2 Crossref
|o 10.1038/nm.4102
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s11427-016-9001-4
|2 Crossref
|o 10.1007/s11427-016-9001-4
999 C 5 |9 -- missing cx lookup --
|a 10.1038/srep13888
|2 Crossref
|o 10.1038/srep13888
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.febslet.2015.10.023
|2 Crossref
|o 10.1016/j.febslet.2015.10.023
999 C 5 |9 -- missing cx lookup --
|a 10.1097/MCO.0b013e32833eebe5
|2 Crossref
|o 10.1097/MCO.0b013e32833eebe5
999 C 5 |9 -- missing cx lookup --
|a 10.3389/fcell.2015.00085
|2 Crossref
|o 10.3389/fcell.2015.00085
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.parkreldis.2017.02.026
|2 Crossref
|o 10.1016/j.parkreldis.2017.02.026
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s10517-017-3700-7
|2 Crossref
|o 10.1007/s10517-017-3700-7
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.cell.2016.11.018.e12
|2 Crossref
|o 10.1016/j.cell.2016.11.018.e12
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.neuroscience.2015.02.008
|2 Crossref
|o 10.1016/j.neuroscience.2015.02.008
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.26069
|2 Crossref
|o 10.1002/mds.26069
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.immuni.2013.12.007
|2 Crossref
|o 10.1016/j.immuni.2013.12.007
999 C 5 |9 -- missing cx lookup --
|a 10.1523/JNEUROSCI.1787-16.2017
|2 Crossref
|o 10.1523/JNEUROSCI.1787-16.2017
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.parkreldis.2016.08.019
|2 Crossref
|o 10.1016/j.parkreldis.2016.08.019
999 C 5 |9 -- missing cx lookup --
|a 10.1136/gutjnl-2015-309618
|2 Crossref
|o 10.1136/gutjnl-2015-309618
999 C 5 |9 -- missing cx lookup --
|a 10.3945/ajcn.116.146928
|2 Crossref
|o 10.3945/ajcn.116.146928
999 C 5 |9 -- missing cx lookup --
|a 10.1111/j.1574-6941.2011.01252.x
|2 Crossref
|o 10.1111/j.1574-6941.2011.01252.x
999 C 5 |9 -- missing cx lookup --
|a 10.1111/jnc.13646
|2 Crossref
|o 10.1111/jnc.13646


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21